2021
DOI: 10.1016/j.healun.2021.01.478
|View full text |Cite
|
Sign up to set email alerts
|

Still Valid: Reassessing A Lung Transplant Recipient Risk of Death Model

Abstract: normal TLs. There was a significant difference in hematologic malignancy rate in those with short TLs (40% vs. 0%, p=0.009). There was no difference in time to cancer diagnosis or survival (Table 3). Conclusion: LTRs with short TLs may be predisposed to hematologic malignancy. Study limitations include size, the single-center, retrospective design, and that only a sub-set of patients had TL measured.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance